Park National Corp OH Invests $14.46 Million in AstraZeneca PLC $AZNCF

Park National Corp OH bought a new position in shares of AstraZeneca PLC (OTCMKTS:AZNCF) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 73,331 shares of the company’s stock, valued at approximately $14,462,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in AZNCF. Hughes Financial Services LLC purchased a new stake in AstraZeneca in the fourth quarter valued at $34,000. Fairscale Capital LLC acquired a new stake in AstraZeneca during the 4th quarter worth about $37,000. Mascoma Wealth Management LLC purchased a new position in shares of AstraZeneca during the 4th quarter valued at about $46,000. Aventus Investment Advisors Inc. purchased a new position in shares of AstraZeneca during the 1st quarter valued at about $46,000. Finally, Resources Management Corp CT ADV acquired a new position in shares of AstraZeneca in the 4th quarter valued at about $61,000. 40.87% of the stock is currently owned by institutional investors and hedge funds.

AstraZeneca Price Performance

Shares of AZNCF stock opened at $187.10 on Friday. AstraZeneca PLC has a 52-week low of $122.26 and a 52-week high of $195.00. The business has a 50-day simple moving average of $187.10 and a 200-day simple moving average of $186.01.

About AstraZeneca

AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.

The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.